Johnson & Johnson agrees to pay $2.2 billion in drug-marketing settlement [1]

By: Brady Dennis, 11/04/2013

Federal investigators accused a Johnson & Johnson subsidiary of promoting Risperdal for controlling anxiety and aggression in elderly dementia patients, as well as for treating behavioral problems in other “vulnerable” populations, such as children and the mentally disabled, even though the Food and Drug Administration initially approved the drug only for schizophrenia. Officials said the company also promoted off-label uses for Invega and “made false and misleading statements about its safety and efficacy.”

 

In addition, Justice officials said another Johnson & Johnson subsidiary undertook an “aggressive campaign” to market Natrecor for some patients with less severe heart disease than the drug was designed to treat.

 

For more on this story visit http://www.washingtonpost.com/national/health-science/johnson-and-johnson-agrees-to-pay-22-billion-in-drug-marketing-settlement/2013/11/04/a7092342-456a-11e3-b6f8-3782ff6cb769_story.html [2]